Regulatory Norgine gets first EU approval for WHIM syndrome therapy PharmaphorumPatients in the EU with the ultra-rare disease WHIM syndrome now have their first approved treatment, Norgine's Xolremdi.Rare DiseaseRead full story pharminent April 30, 2026 (Last updated: April 30, 2026) Pharmaphorum Patients in the EU with the ultra-rare disease WHIM syndrome now have their first approved treatment, Norgine’s Xolremdi. Rare Disease Read full story Post navigation Previous: Regeneron Q1 2026 net income falls 10% to $727mNext: GSK-partnered Alector hit with third neuro failure as Alzheimer’s asset disappoints Related Stories Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026 Regulatory HHS appoints permanent FDA CBER, CDER heads pharminent September 10, 2026 Regulatory FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer pharminent September 7, 2026